High perfusion pressure as a predictor of reperfusion pulmonary injury after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension  by Kinutani, Hiroto et al.
IJC Heart & Vasculature 11 (2016) 1–6
Contents lists available at ScienceDirect
IJC Heart & Vasculature
j ourna l homepage: ht tp : / /www. journa ls .e lsev ie r .com/ i jc -hear t -and-vascu la tureHigh perfusion pressure as a predictor of reperfusion pulmonary injury
after balloon pulmonary angioplasty for chronic thromboembolic
pulmonary hypertensionHiroto Kinutani, Toshiro Shinke ⁎, Kazuhiko Nakayama, Yu Taniguchi, Hiromasa Otake, Tomofumi Takaya,
Tsuyoshi Osue, Akihide Konishi, Noriaki Emoto, Ken-ichi Hirata
Kobe University Graduate School of Medicine, Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe, JapanAbbreviations: BPA, balloon pulmonary angioplasty
output; CT, computed tomography; CTEPH, chronic
hypertension; IVUS, intravascular ultrasound; MLD, mi
non-invasive positive pressure ventilation; PAG, pulmonar
arterial pressure; PCWP, pulmonary capillary wedge pres
ectomy; Pd, mean pulmonary arterial pressure distal to th
arterial pressure proximal to the stenosis; PVR, pulmo
receiver-operating characteristic; RPI, reperfusion pulmo
dence interval.
⁎ Corresponding author at: Division of CardiovascularM
Medicine, Kobe University Graduate School of Medicine,
Kobe, Hyogo 650-0017, Japan.
E-mail address: shinke@med.kobe-u.ac.jp (T. Shinke).
http://dx.doi.org/10.1016/j.ijcha.2015.11.006
2352-9067/© 2015 The Authors. Published by Elsevier Irea b s t r a c ta r t i c l e i n f oArticle history:
Received 11 September 2015
Received in revised form 24 November 2015
Accepted 25 November 2015
Available online 26 November 2015Background: Clinical efﬁcacy of balloon pulmonary angioplasty (BPA) to the patients with non-operable chronic
thromboembolic pulmonary hypertension (CTEPH) for improving pulmonary hemodynamics and exercise
tolerance has been reported in these several years. However, reperfusion pulmonary injury (RPI) remains to
be a major complication of BPA to overcome. This study elucidated the local predictor of RPI.
Methods: Twenty-eight consecutive patients with non-operable CTEPH underwent BPA for lesions in the
segmental or sub-segmental vessels. Pre- and post-BPA pulmonary arterial pressures at proximal (Pp) and distal
(Pd) to the stenosis were measured by a 0.014-in. pressure wire. Positive or negative RPI was evaluated by chest
computed tomography in each re-perfused segment separately 4 h after BPA.
Results: Pressuremeasurements pre- and post-BPAwere obtained from 110 lesions, where Pd and pressure ratio
(Pd/Pp) increased after BPA in all lesions. Among them, RPI was observed in 49 lesions (44.5%). In the
RPI-positive lesions, post-BPA Pd and post-BPA Pd/Pp were higher compared with the RPI-negative lesions.
Multivariate logistic analysis revealed that the post-BPA Pd was independently associated with RPI incidence.
Receiver operating characteristic curve analysis demonstrated the best cut-off value of 19.5 mm Hg for post-
BPA Pd to predict RPI.
Conclusions: High reperfusion pressure after BPA could be a predictor of RPI. Monitoring local pressure during
BPA procedure may have a potential to reduce the incidence of RPI.
© 2015 TheAuthors. Published by Elsevier Ireland Ltd. This is an openaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Predictor1. Introduction
Chronic thromboembolic pulmonary hypertension (CTEPH) is
characterized by the obstruction of the pulmonary arteries with orga-
nized thrombus and intraluminal ﬁbrous tissue, which leads to elevated
pulmonary vascular resistance (PVR), severe pulmonary hypertension,
and right heart failure [1–5]. In addition, if appropriate medical
intervention is not provided, the prognosis of patients with CTEPH is; CI, cardiac index; CO, cardiac
thromboembolic pulmonary
nimal lumen diameter; NIPPV,
y angiography; PAP, pulmonary
sure; PEA, pulmonary endarter-
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edicine, Department of Internal
7-5-1 Kusunoki-cho, Chuo-ku,
land Ltd. This is an open access articlextremely poor, with a reported only 10% ﬁve-year survival rate in
patients with a mean pulmonary arterial pressure (PAP) of N50 mm Hg
[6]. In this context, pulmonary endarterectomy (PEA) is a gold standard
of treatment that can dramatically reduce PAP and improve the progno-
sis of patients with CTEPH [7–9]. However, PEA for CTEPH with periph-
erally located organized thrombi has been reported to be less effective
for the improvement in pulmonary hemodynamics and a higher periop-
erative mortality rate compared with that for CTEPH with proximal
thrombi [10,11]. Thus, it has been reported that up to 40% of patients
with CTEPHwere considered non-operable, due to peripherally located
organized thrombus or other comorbidities [7]. Therefore, a safer and
more effective treatment for non-operable CTEPH is urgently needed.
The ﬁrst report of balloon pulmonary angioplasty (BPA) for a patient
with CTEPHwas published in 1988 [12]. In 2001, Feinstein et al. reported
marked improvements in the pulmonary hemodynamics and exercise
tolerance in the series of BPA to 18 patients with CTEPH [13]. Recent
several studies reported the reﬁned BPA procedure and agitated the
interest of many interventionists due to its clinical efﬁcacy [14–18]. In
addition, we have reported that BPA could achieve comparable reduc-
tion in mean PAP with PEA [15]. At the same time, reperfusione under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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solved. Previous reports have shown that RPI after BPA occurred in
53–64% of cases [13–16]. RPI includes hemosputum, worsening of hyp-
oxemia, or increased density of chest computed tomography (CT) in the
dilated segment regardless of symptoms [14]. RPI is thought to be
caused by pulmonary edema and/or pulmonary bleeding. Because of
the difﬁculty to differentiate between these etiologies by only chest X-
ray or CT, it is called reperfusion pulmonary “injury”. Although it has
been hypothesized that exposure to high reperfusion pressure after bal-
loon dilation may lead to RPI [14], no published reports have monitored
the local pressure around the stenosis before and after BPA. In the pres-
ent study, we analyzed the effect of BPA on the local pressure hemody-
namics, and investigated whether the local pressure might be a
predictor of RPI.
2. Methods
2.1. Patient enrollment
Between October 2012 and April 2015, 48 patients were diagnosed
as CTEPH at Kobe University Hospital in Japan. The diagnosis of CTEPH
was established according to the published clinical guidelines [19]. All
patients had a more than 25 mm Hg of mean PAP and less than
15 mm Hg of pulmonary capillary wedge pressure (PCWP), and were
deﬁnitively diagnosed as CTEPH after identiﬁcation of multiple stenosis
and obstruction of the bilateral pulmonary arteries via pulmonary
angiography (PAG). The distribution of the thromboembolic lesions
and intimal thickening of the pulmonary artery was evaluated using
contrast-enhanced chest CT and PAG, and the results were reviewed
by experienced cardiologists, cardiovascular surgeons, and radiologists.
The assessment of operability was conducted by cardiologists and
cardiovascular surgeons according to the criteria for PEA [20], which
consider the distribution of stenosis, obstruction, and intimal thicken-
ing, age, and comorbidities. Based on these assessments, 19 patients
were judged to be operable and underwent PEA, while 29 patients
were judged to be non-operable and therefore suitable for BPA. Only
data from BPA were included in this analysis.
The design of the present studywas approved by the Ethics Commit-
tee of Kobe University, and conformed to the tenets of theDeclaration of
Helsinki. All enrolled patients provided their informed written consent.
2.2. Hemodynamic and exercise tolerance analysis
We performed right heart catheterization and measured the PAP,
right atrial pressure, and PCWP using a ﬂow-directed thermodilution
catheter immediately before the ﬁrst BPA procedure in each patient.
PVR and cardiac output (CO) were calculated using the Fick method.
In addition, 6-min walk distance and the World Health Organization
functional class were obtained 1 or 2 days before the ﬁrst BPA
procedure.
2.3. Balloon pulmonary angioplasty and pulmonary arterial pressure
analysis
In each BPA session,we placed a 9-Fr sheath (XEMEX Introducer Set,
Zeon Medical, Tokyo, Japan) into the vein (typically into the femoral
vein or the internal jugular), and then brought a 70 cm or 90 cm 6-Fr
Britetip sheath introducer (BRITE TIP® Interventional Sheath Introducer;
Cordis/Johnson & Johnson, Bridgewater, NJ, USA) to themain pulmonary
artery via the 9-Fr sheath, using a Radifocus 0.035-in. guide wire
(Terumo, Tokyo, Japan) and a 5-Fr pigtail catheter (Goodtec catheter,
Goodman, Aichi, Japan). When the sheath was inserted, an initial dose
of heparin (2000–5000 U) was administered, and 1000 U of heparin
was administered every hour to maintain 200–300 s of intra-operative
activated clotting time. We then selected a segmental or sub-
segmental pulmonary artery using a 6-Fr guide catheter (Autobahn;Multipurpose, or Judkins right 4.0; NIPRO Corporation, Osaka, Japan)
via the long sheath, and performed angiography to identify any stenoses
or occlusions. A 0.014-in. guidewire (Cruise; Asahi Intecc, Aichi, Japan or
Chevalier 14 Floppy, FMD, Saitama, Japan)was passed through the target
lesions under the support of a microcatheter (Prominent Raptor, Tokai
Medical Products, Aichi, Japan). Using intravascular ultrasound (IVUS)
(Eagle Eye® Platinum; Volcano Corp, Rancho Cordova, CA, USA), we
measured the vessel diameter at the site of the thrombi [14], and the
lesions were dilated to an appropriate size using balloon catheters
(2.0–9.0 mm, depending on the diameter of the vessel). To prevent
pulmonary arterial injury, the maximum balloon size was slightly
smaller than the actual vessel diameter, and did not exceed 90% of the
actual vessel diameter [14]. The procedures were repeated on other
segments after one week interval during the same admission until the
mean PAP had normalized. RPI symptom comprises hemosputum,
desaturation, intratracheal intubation, hemodynamic compromise
which needs percutaneous cardiopulmonary support and peri-
procedural mortality. Procedure time for one BPA session was limited
up to 2 h for safety assurance. If necessary, we administrated oxygen or
non-invasive positive pressure ventilation (NIPPV) to the patient.
2.4. Angiographic analysis
Pulmonary angiographic data before and immediately after BPA
were analyzed using edge-detection techniques (QCA-CMS5.1, Medis
Imaging Systems, Leiden, The Netherlands). The quantitative angio-
graphic parameters included: (1) the minimal lumen diameter (MLD),
(2) the reference vessel diameter,whichwasmeasured at an apparently
normal area proximal to the target stenosis, (3) the vessel expansion
ratio, which was deﬁned as the MLD after balloon expansion divided
by the MLD before the wire passed through the lesion, and (4) the
balloon-vessel ratio, whichwas deﬁned as the balloon diameter divided
by reference vessel diameter before the BPA.
2.5. Pulmonary arterial pressure assessment
The local PAP was measured at proximal and distal to the stenosis.
Exclusion criteria for pressure assessment included severe bending
lesions, uncrossable lesions, lesions without pressure gradient, and
lesions with short peripheral margin. After we passed a 0.014-in.
guide wire through the target lesion, the guide wire was changed to a
pressure wire (Aeris, Saint Jude Medical Systems, Uppsala, Sweden).
After dilation of the stenosis by balloon catheter, we performed
additional assessments of the mean proximal and distal PAPs. Pp was
deﬁned as the mean PAP proximal to the stenosis measured at the tip
of guiding catheter and Pd as the mean PAP distal to the stenosis mea-
sured using the pressure wire sensor. The pressure ratio was calculated
as Pd divided by Pp, and the absolute increase in Pd as the post-BPA Pd
was subtracted by the pre-BPA Pd.
2.6. Computed tomography analysis
4 h after each BPA session, we took chest CT to evaluate incidence
and location of RPI. RPI was deﬁned when there was any increase in
density (regardless of the size) observed on CT image in the correspond-
ing pulmonary segment of the dilated pulmonary artery (Fig. 1). All CT
imageswere analyzed by two independent observerswhowere blinded
to all clinical information. When the two observers' decisions were
inconsistent, a third observer analyzed the images for making the ﬁnal
decision.
2.7. Statistics analysis
All datawere presented asmean± standard deviation or odds ratios
and 95% conﬁdence intervals (95%CI), unless otherwise stated. Analyses
were performed using SPSS statistical software (v. 17.0, SPSS, Chicago,
Fig. 1.Representative case of computed tomography imaging of the reperfusion pulmonary injury. (A) Chest CT image before the BPA. (B) Chest CT image 4 h after the BPA. During the BPA,
the right pulmonary artery A10 was dilated, and the density of S10 increased during chest CT imaging as the reperfusion pulmonary injury occurred in S10. BPA: balloon pulmonary
angioplasty, CT: computed tomography.
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signiﬁcant. Student's t test was used for all normally distributed
variables, and the Mann–Whitney U test or Wilcoxon matched-pairs
signed-rank test were used for non-normally distributed variables, as
appropriate. Comparisons of proportions were performed using the
chi-square test or Fisher's exact test. Inter- and intra-observer reliability
was assessed using the kappa test for chest CT diagnosis of RPI. Univari-
ate logistic regression analysis was used to examine the relationship
between the incidence of RPI and the predictive variables. Multivariate
logistic regression analysis was used to examine the independent effect
of each variable on the incidence of RPI. The optimum predictive thresh-
old for RPIwas evaluated using a receiver-operating characteristic (ROC)
curve, and the Youden index was used to deﬁne the optimum cut-off
value on the ROC curve.
3. Results
3.1. Baseline patient characteristics
Among the 29 patients who were deemed unsuitable for PEA and
were enrolled for BPA, one in-hospital death resulted from infectionTable 1
Baseline patient characteristics.
Variables n = 28
Female, n (%) 19 (67.9%)
Age, years 64.8 ± 12.1
WHO functional class, I/II/III/IV 0/8/16/4
6MWD, m 303.0 ± 91.9
Heart rate, beat/min 72.0 ± 8.4
Systolic PAP, mm Hg 61.1 ± 18.8
Diastolic PAP, mm Hg 19.7 ± 5.8
Mean PAP, mm Hg 34.2 ± 10.4
PCWP, mm Hg 7.9 ± 2.4
RAP, mm Hg 4.8 ± 2.3
CO, L/min 4.1 ± 1.3
PVR, dyne/s/cm5 574.4 ± 316.7
BNP, pg/ml 160.4 ± 233.4
Warfarin, n (%) 28 (100)
Administration of pulmonary vasodilators, n (%) 20 (71.4)
PGI2, n (%) 5 (17.9)
ERAs, n (%) 16 (57.1)
PDE-5 inhibitors, n (%) 6 (21.4)
sGC 1 (3.6%)
Values are mean± SD or percent. BNP, brain natriuretic peptide; CO, cardiac output; ERA,
endothelin receptor antagonist; PAP, pulmonary artery pressure; PCWP, pulmonary
capillary wedge pressure; PDE-5, phosphodiesterase type 5; PGI2, prostaglandin analog;
PVR, pulmonary vascular resistance; RAP, right atrial pressure; sGC, soluble guanylate
cyclase activator; WHO, World Health Organization; 6MWT, 6 min walk test.via the central venous catheter thatwas used to administer epoprostenol
before the BPA. Therefore, 28 patients underwent BPA, and their baseline
characteristics are shown in Table 1.3.2. BPA results
A total of 84 BPA sessions were performed for the 28 patients
(average, 3.0 ± 1.4 sessions per patient), and their hemodynamics
and exercise tolerance signiﬁcantly improved after the BPA procedures
(Table 2). Regarding periprocedural complications, one or more RPI
symptoms occurred in 56 sessions (66.7%). Hemosputumwas observed
in 14 sessions (16.7%), and desaturation requiring NIPPV was observed
in 13 sessions (15.4%). None of the patients required intratracheal
intubation or percutaneous cardiopulmonary support, and no one died
(Table 3).3.3. Lesions, procedural characteristics, and angiographic analysis
Based on the exclusion criteria, we excluded 5 patients from the
local pulmonary artery pressure measurements. Therefore, Pp and Pd
data (with chest CT data) were obtained from 110 lesions in 23 patients
(Fig. 2). The results of the angiographic analysis are shown in Table 4.
MLD (from 2.22 ± 1.18 to 3.39 ± 1.30 mm, p b 0.01) and reference
vessel diameter (from 5.50 ± 1.86 mm to 6.10 ± 1.75, p b 0.01) were
signiﬁcantly increased after balloon dilatation as showing 1.94 ± 1.28
of a vessel expansion ratio.Table 2
Hemodynamics and exercise tolerance before and after BPA.
Variables Before BPA After BPA p value
WHO Fc 0/8/16/4 16/11/1/0 b0.01
6MWD, m 303.0 ± 91.9 394.7 ± 124.2 b0.01
HR, beat/min 72.0 ± 8.4 69.1 ± 10.3 0.10
sPAP, mm Hg 61.1 ± 18.8 33.1 ± 8.7 b0.01
dPAP, mm Hg 19.7 ± 5.8 10.5 ± 4.3 b0.01
mPAP, mm Hg 34.2 ± 10.4 19.2 ± 5.7 b0.01
PCWP, mm Hg 7.9 ± 2.4 6.4 ± 2.3 0.02
RAP, mm Hg 4.8 ± 2.3 2.9 ± 2.1 b0.01
CO, L/min 4.1 ± 1.3 4.5 ± 1.6 0.14
PVR, dyne/s/cm5 574.4 ± 316.7 258.3 ± 170.7 b0.01
BNP, pg/ml 160.4 ± 233.3 26.1 ± 30.5 b0.01
Values aremean± SD. BNP, brain natriuretic peptide; CO, cardiac output; PAP, pulmonary
artery pressure; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular
resistance; RAP, right atrial pressure; WHO, World Health Organization; 6MWT, 6 min
walk test.
Table 3
Complications related to BPA.
Variables n = 84
Wire perforation, n (%) 5 (6.0)
RPI, n (%) 56 (66.7)
Right heart failure required for PCPS, n (%) 0 (0)
Desaturation required for intratracheal intubation, n (%) 0 (0)
Desaturation required for NIPPV, n (%) 13 (15.4)
Hemosputum, n (%) 14 (16.7)
Only CT scan, n (%) 39 (46.4)
Death, n (%) 0 (0)
None, n (%) 28 (33.3)
Data indicates the number of sessions. The number of RPI indicates the number of session
one or more RPI symptoms occurred. NIPPV, non-invasive positive pressure ventilation;
only CT scan, increased density of the dilated segment detected by a chest CT scanwithout
any symptoms; PCPS, percutaneous cardiopulmonary support; RPI, reperfusion pulmo-
nary injury.
Table 4
Lesion and angiographic analysis.
Variables n = 77
Side, right/left, n (%) 72 (64.9)/38 (34.2)
Lobe, superior/middle/inferior, n (%) 22 (19.8)/2 (1.8)/86 (77.5)
Pre-BPA reference vessel diameter, mm 5.50 ± 1.86
Post-BPA reference vessel diameter, mm 6.10 ± 1.75⁎⁎
Pre-BPA MLD, mm 2.22 ± 1.18
Post-BPA MLD, mm 3.39 ± 1.30⁎⁎
Vessel expansion ratio 1.94 ± 1.28
Final balloon diameter, mm 5.26 ± 1.44
Balloon-vessel ratio 0.89 ± 0.21
Values are mean ± SD or percent. BPA, balloon pulmonary angioplasty; MLD, minimal
lumen diameter.
⁎⁎ p value was b0.01 compared with before BPA.
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Before the BPA, a pressure gradient was observed across the pulmo-
nary artery stenosis (mean Pp: 26.5 ± 7.5 mm Hg; mean Pd: 11.3 ±
7.2 mm Hg; p = 0.027, mean pressure gradient: 15.4 ± 8.8 mm Hg).
After the BPA, the Pp slightly decreased (from 26.5 ± 7.5 mm Hg to
25.7 ± 7.5 mm Hg, p b 0.01), the post-BPA Pd (from 11.3 ± 7.2 mm Hg
to 19.9 ± 7.9 mm Hg, p b 0.01) and the post-BPA pressure ratio signiﬁ-
cantly increased (from 0.44 ± 0.25 to 0.76 ± 0.19, p b 0.01) (Table 5).
3.5. Computed tomography analysis
Based on the CT analysis, RPI under the dilated lesionwere observed
in 49 (44.5%) lesions. Inter- and intra-observer reliability testing (testedFig. 2. Study ﬂow chart. BPA, balloon pulmonary angioplasty; CTEPH, chronic thromboembo
mentioned in the main text.at N30 days apart) regarding the diagnosis of RPI exhibited good agree-
ment (kappa = 0.947 and 0.947, respectively).
3.6. RPI analysis
In the analysis based on the dilated lesions, a comparison of the RPI-
positive and RPI-negative groups is shown in Table 6, although no
signiﬁcant differences were observed in location of targeted pulmonary
artery, pre-BPA Pd, pre-BPA pressure ratio, the vessel expansion ratio, or
balloon-vessel ratio between the two groups. However, the RPI-positive
group had signiﬁcantly higher pre-BPA Pp (30.3 ± 6.1 vs. 23.4 ±
7.4 mm Hg, p b 0.01), post-BPA Pp (29.5 ± 6.2 vs. 22.7 ± 7.2 mm Hg,
p b 0.01), post-BPA Pd (24.3 ± 6.4 vs. 16.4 ± 7.2 mm Hg, p b 0.01),
post-BPA pressure ratio (0.83 ± 0.14 vs. 0.71 ± 0.21, p b 0.01), and
absolute Pd increase (12.5 ± 8.4 vs. 5.5 ± 5.0 mm Hg, p b 0.01), com-
pared with the RPI-negative group. Multivariate analysis revealed thatlic pulmonary hypertension; PEA, pulmonary endarterectomy. *: Exclusion criteria are
Table 5
Local pulmonary artery pressure analysis.
Variables (n = 77) Pre-BPA Post-BPA p value
Pp, mm Hg 26.5 ± 7.5 25.7 ± 7.5 0.008
Pd, mm Hg 11.3 ± 7.2 19.9 ± 7.9 b0.01
Pressure ratio 0.44 ± 0.25 0.76 ± 0.19 b0.01
Values are mean± SD. BPA, balloon pulmonary angioplasty; Pd, mean pulmonary arterial
pressure distal to the stenosismeasured by the pressurewire sensor; Pp,mean pulmonary
arterial pressure proximal to the stenosis measured by the guiding catheter.
Table 7
Multivariate analysis to examine the independent effect of each variable on the occurrence
of RPI.
Variables Univariate analysis Multivariate analysis
Odds
ratio
95% CI p value Odds
ratio
95% CI p value
Pre-BPA Pp 1.159 1.083–1.2040 b0.001
Post-BPA Pp 1.156 1.082–1.235 b0.001
Post-BPA Pd 1.191 1.106–1.284 b0.001 1.139 1.053–1.231 0.001
Pd increase 1.185 1.097–1.280 b0.001 1.126 1.033–1.229 0.007
Pre-BPA MLD 0.689 0.483–0.982 0.040
BPA, balloon pulmonary angioplasty;MLA,minimal lumendiameter; Pd,mean pulmonary
arterial pressure distal to the stenosis measured by the pressure wire sensor; Pp, mean
pulmonary arterial pressure proximal to the stenosis measured by the guiding catheter.
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1.139, 95% CI: 1.053–1.231, p = 0.001) (Table 7). The area under ROC
curve of post-BPA Pd for predicting RPI was 0.814, with an optimum
cut-off value of 19.5 mm Hg (sensitivity: 79.6%, speciﬁcity: 75.4%)
(Fig. 3).
4. Discussion
As recently reported, BPAhas the potential to improvehemodynamics
and exercise tolerance in patients with inoperable CTEPH. However, no
consensus has been established in technical aspects of BPA procedure,
so that various clinical efﬁcacies onhemodynamics and prognosis derived
from individual optimization have been reported [13–18]. So, there is an
urgent need for establishing the indexwhich guides us to safer andmore
effective BPA. For example, although Feinstein et al. achieved a 21%
decrease in mean PAP, ﬁnal PAP was still so far above the normal
range that it would raise relatively high incidence of intratracheal
intubation (17%), and periprocedural mortality (5.6%) [13]. In contrast,
Mizoguchi et al. achieved a 47% decrease in the mean PAP through
routine use of IVUS, with lower complications of severe RPI (6%) and
periprocedural mortality (1.5%) [14]. Therefore, IVUS can potentially
reduce operative complications by facilitating to select optimal balloon
size. In the present study, we also used IVUS in a similar way used by
Mizoguchi et al., andwe achieved a 44% decrease in themean PAPwith-
out any severe complications like intratracheal intubation or resulted in
periprocedural death.
At the same time, despite the use of IVUS, Mizoguchi et al. reported
RPI in 60% of their procedures and we also observed RPI in 66.7% of our
procedures. Now therefore, the high incidence of RPI still remains as an
issue for BPA. These ﬁndings indicate that routine use of IVUS does not
sufﬁciently reduce the incidence of RPI. Several groups recommend
the limitation of the number of treatment lesions for the prevention of
severe desaturation caused by RPI, whereas this strategy would likely
reduce the overall efﬁcacy of BPA. Therefore other monitoring method-
ologies are desired for further improvement of safety and efﬁcacy.
It has been hypothesized that exposure of high reperfusion pressure
to the reperfused area after balloon dilationmay lead to RPI [14,18], andTable 6
Comparison between RPI-positive group and RPI-negative group.
Variables RPI-positive group
(n = 49)
RPI-negative group
(n = 61)
p value
Side, right/left, n (%) 28 (57.1)/21 (42.9) 44 (72.1)/17 (27.9) 0.10
Lobe, superior/middle/
inferior, n (%)
11 (22.4)/0 (0)/38
(77.6)
11 (18.0)/2 (3.3)/48
(78.7)
0.51
Vessel expansion ratio 1.64 ± 0.45 2.45 ± 6.21 0.25
Balloon-vessel ratio 0.89 ± 0.19 0.89 ± 0.22 0.99
Pre-BPA Pp, mm Hg 30.3 ± 6.1 23.4 ± 7.4 b0.01
Pre-BPA Pd, mm Hg 11.8 ± 7.6 10.9 ± 6.8 0.53
Pre-BPA pressure ratio 0.40 ± 0 .27 0.46 ± 0.23 0.23
Post-BPA Pp, mm Hg 29.5 ± 6.2 22.7 ± 7.2 b0.01
Post-BPA Pd, mm Hg 24.3 ± 6.4 16.4 ± 7.2 b0.01
Post-BPA pressure ratio 0.83 ± 0.14 0.71 ± 0.21 b0.01
Pd increase, mm Hg 12.5 ± 8.4 5.5 ± 5.0 b0.01
Values are mean ± SD or percent. BPA, balloon pulmonary angioplasty; Pd, mean
pulmonary arterial pressure distal to the stenosis measured by the pressure wire sensor;
Pp, mean pulmonary arterial pressure proximal to the stenosis measured by the guiding
catheter.Feinstein et al. have reported that RPI was frequently in the patients
with N35 mm Hg of mean PAP before BPA [13]. However, no previous
study has assessed the relation between the local pressure and safety
before and after BPA, and this study is the ﬁrst documentation which
clariﬁes the association between distal reperfusion pressure and the
incidence of RPI (Fig. 4). In addition, we identiﬁed an optimal cut-off
value (19.5 mm Hg) as a novel monitoring parameter to assure stable
BPA result. We would like to suggest that combined strategy with
IVUS for selecting an appropriate balloon size and a pressure wire for
monitoring distal perfusion pressure would facilitate safe and effective
BPA procedures, which will allow more aggressive BPA by increasing
the target number of dilations in one session.
4.1. Study limitations
There were several limitations in the present study. First, female
patients were noticeably more likely to undergo BPA (67.9% in this
study). Although it has been reported that there is no sex-related bias
for the incidence of CTEPH, it has also been reported that 72.2% of
Japanese patients with CTEPH are women (per the Respiratory Failure
Research Group from the Ministry of Health, Labor and Welfare, Japan
[21]). Therefore, we believe that the predominance of women was notFig. 3. Receiver operating characteristic curve of post-BPA Pd for predicting RPI. The arrow
indicates the optimal cut-off value for predicting reperfusion pulmonary injury after
balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension.
AUC: area under the curve, CI: conﬁdence interval.
Fig. 4. Both pulmonary artery right A2 and A3 were dilated by BPA. RPI was observed in
pulmonary segment 2 where Pd changed from 10 to 28 mm Hg, but not observed in
pulmonary segment 3 where Pd changed from 8 to 19 mmHg. BPA, balloon pulmonary
angioplasty; Pd, mean pulmonary arterial distal to the stenosis; Pp, mean pulmonary
arterial proximal to the stenosis; RPI, reperfusion pulmonary injury.
6 H. Kinutani et al. / IJC Heart & Vasculature 11 (2016) 1–6related to any selection bias in the present study. Second, this was a
single-center study with a small sample size, therefore a multi-center
trial with a larger number of patients is needed to conﬁrm our ﬁndings.
Third, although post-BPA RPI was observed in 66.7% of the procedures,
modest desaturation requiring NIPPV occurred in 15.4% of the sessions
even if there is no need of intratracheal intubation or extracorporeal
lung assistance. The relationship between CT-diagnosed RPI and the
clinical symptoms of hypoxia was not analyzed, and further studies
are needed to clarify the degree of RPI that can cause hypoxia. Finally,
the long-term efﬁcacy of BPA was not evaluated in this study, and it
needs to be further investigated.5. Conclusion
Overloaded high reperfusion pressure after BPA would be an
independent predictor for RPI. Monitoring the local pressure changes
during BPA may help reduce the incidence of RPI.Conﬂict of interest
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